Long-term anticoagulant therapy in patients with coronary artery disease

European Heart Journal

Volumn 27, Issue 8, 2006, Pages 913-919

  Husted, S E ^a   Ziegler, B K ^a   Kher, A ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Bartholinbygningen University of Aarhus ^*  (France)

Author keywords

AMI; Anticoagulation; Coronary artery disease; Prophylaxis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANISTREPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; DALTEPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; THROMBIN INHIBITOR; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; GASTRITIS; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CORONARY ARTERIOSCLEROSIS; DRUG COMBINATIONS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; VITAMIN K;

EID: 33645466135     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi714     Document Type: Review

References (34)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):204S-233S.
2. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):188S-203S.
3. Weitz JI, Crowther M. Direct thrombin inhibitors. Review. Thromb Res 2002;106:V275-V284.
4. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-2067.
5. Alpert JS, Thygesen K, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513.
6. Neri Serneri GG, Rovelli F, Gensini GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987;1:937-942.
7. An International Anticoagulant Review Group.Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet 1970;1:203-209.
8. Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-994.
9. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
10. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
11. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS Trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994;89:81-88.
12. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, revascularisation procedures in patients with acute myocardial ischaemia without STelevation: a randomised trial. Lancet 1999;353:429-438.
13. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001;37:475-484.
14. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-715.
15. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:701-707.
16. Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German-Austrian Aspirin Trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation 1980;62:V63-V72.
17. EPSIM Research Group. A controlled comparison of aspirin oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708.
18. Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER Study): a multicentre unblinded randomised clinical trial. BMJ 1996;313:1429-1431.
19. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-396.
20. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP Study. Circulation 2002;105:557-563.
21. Herlitz J, Holm J, Peterson M. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J 2004;25:232-239.
22. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 Study): a randomised controlled trial. Lancet 2002;360:109-113.
23. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974.
24. Brouwer MA, van den Bergh PJ, Aengevaeren WR, Veen G, Luijten HE, Hertzberger DP, van Boven AJ, Vromans RP, Uijen GJ, Verheugt FW. Aspirin plus coumarin vs aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002;106:659-665.
25. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodwin A, Nyström P, Bylock A, for the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-797.
26. ten Berg JM, Kelder JC, Suttorp MJ, Mast EG, Bal E, Ernst SM, Verheugt FW, Plokker HW. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. Circulation 2000;102:386-391.
27. Brouwer MA, Verheugt FW. Oral anticoagulation for acute coronary syndromes. Circulation 2002;105:1270-1274.
28. Becker RC. Antithrombotic therapy after myocardial infarction. N Engl J Med 2002;347:1019-1022.
29. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
30. Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol 2001;21:2093-2098.
31. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, stroke in high risk patients. BMJ 2002;324:71-86.
32. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002;88:711-715.
33. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg RR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes PURSUIT Investigators. Platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. Am J Cardiol 1999;83:1147-1151.
34. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.